The Canadian Intellectual Property Office has granted patent No.2,446,356 to Quick-Med Technologies' MultiStat family of patented matrix metalloproteinase inhibitors (MMPIs).
MultiStat family, which comprises of 10 patented compounds, are designed to treat Rosacea by preventing and repairing skin damage.
The patent covers claims that address methods for treating rosacea with an antimicrobial, a retinoid, and an inhibitor of toll-like receptors in both topical and oral applications.
The company said antimicrobials to be used in combination with its MultiStat family includes tetracycline, erythromycin, azithromycin, clarithromycin, milbemycin, aminoglycoside, penicillin, cephalosporin, fluoroquinolone, streptogramin and sulfanomide.
Quick-Med president Bernd Liesenfeld said the company’s MultiStat technology has shown significant improvement in the appearance of skin, by promoting the maintenance, healing and repair.
"We are pleased that this granted patent will allow us to license our MultiStat patent estate to help a broad population looking for products that provide relief from Rosacea skin conditions," Liesenfeld added.